OMSAV PHARMA
GenericsOMSAV PHARMA is a generic drug manufacturer focused on Infectious Disease, Cardiovascular.
OMSAV PHARMA's Key Drugs
OMSAV PHARMA's key approved drugs from the last 15 years (excludes generics, biosimilars and IV formulations).
OMSAV PHARMA's Recent FDA Approvals
New NDA/BLA approvals for OMSAV PHARMA over the last two years — novel drugs only, excluding generics and label supplements.
OMSAV PHARMA's Therapeutic Areas
OMSAV PHARMA's approved drugs and pipeline span 2 therapeutic areas, led by Infectious Disease and Cardiovascular, across 0 biologic and 0 small-molecule drugs. Weighted by commercial stage — approved drugs count most, then late-stage trials.
OMSAV PHARMA's Top Competitors
OMSAV PHARMA's closest competitors by therapeutic-area and drug-target overlap include Merck, Baxter, and Sanofi. Ranked by overlap in therapeutic areas and drug targets across approved drugs and pipeline.
OMSAV PHARMA Pipeline Snapshot
Active clinical trials for OMSAV PHARMA across all therapeutic areas, from ClinicalTrials.gov.
Pro Intelligence Preview
Deep insights for investors and analysts
Revenue Insights
- • Top drug revenue breakdown
- • Drug-level revenue analysis
Trial Catalysts
- • Infectious Disease pipeline focus
- • Phase 3 readout tracking
Patent Risk
- • Patent expiration timeline
- • Revenue at risk analysis
Compare Companies
- • Side-by-side pipeline analysis
- • Revenue & market share comparison
Revenue forecasts • Trial milestones • Patent risk modeling
Active (0)
Discontinued (0)
Company Info
- First Approval
- 2023-11-03
- Latest
- 2026-04-22
- Applications
- 2